Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells

OncoImmunology

Volumn 6, Issue 8, 2017, Pages

  Hanoteau, Aurélie ^a   Henin, Coralie ^a   Svec, David ^b   Bisilliat Donnet, Charlotte ^a   Denanglaire, Sébastien ^a   Colau, Didier ^d   Romero, Pedro ^c   Leo, Oberdan ^a   Van den Eynde, Benoit ^d   Moser, Muriel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

CD8+ T cells; cyclophosphamide; effector function; exhaustion; tumor specific immunity

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GILVETMAB; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 7; PERFORIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; EXHAUSTION; FLOW CYTOMETRY; GENE EXPRESSION; GENOMICS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; TUMOR GROWTH;

EID: 85026857133     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1318234     Document Type: Article

References (35)

1. Abu Eid R, Razavi GSE, Mkrtichyan M, Janik J, Khleif SN. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res 2016; 4:377-82; PMID:27196429; https://doi.org/10.1158/2326-6066.CIR-16-0048
2. Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007; 6:880-5; PMID:17582217; https://doi.org/10.4161/cbt.6.6.4090
3. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; https://doi.org/10.1200/JCO.2009.23.7370
4. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71:5601-5; PMID:21846822; https://doi.org/10.1158/0008-5472.CAN-11-1316
5. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28:690-714; PMID:26678337; https://doi.org/10.1016/j.ccell.2015.10.012
6. Hanoteau A, Henin C, Moser M. The interplay of immunotherapy and chemotherapy, a novel approach. Méd Sci M/S 2016; 32:353-61; PMID:27137692; https://doi.org/10.1051/medsci/20163204013
7. Ge Q, Hu H, Eisen HN, Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. PNAS 2002; 99:2989-94; PMID:11880642; https://doi.org/10.1073/pnas.052714099
8. + T cells. J Exp Med 2005; 202:907-12; PMID:16203864; https://doi.org/10.1084/jem.20050732
9. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192:557-64; PMID:10952725; https://doi.org/10.1084/jem.192.4.557
10. Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol 1999; 162:3534-40; PMID:10092811; http://www.jimmunol.org/content/162/6/3534
11. + T cells. Int J Cancer 2014; 134:2841-52; PMID:24249003; https://doi.org/10.1002/ijc.28617
12. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 2008; 205:625-40; PMID:18316415; https://doi.org/10.1084/jem.20071641
13. + T cells in vivo. Eur J Immunol 2012; 42:320-9; PMID:22102057; https://doi.org/10.1002/eji.201142091
14. Apetoh L, Smyth MJ, Drake CG, Abastado J-P, Apte RN, Ayyoub M, Blay J-Y, Bonneville M, Butterfield LH, Caignard A, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology 2015; 4:e998538; PMID:26137416; https://doi.org/10.1080/2162402X.2014.998538
15. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009; 206:51-9; PMID:19139168; https://doi.org/10.1084/jem.20081242
16. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007; 204:345-56; PMID:17261634; https://doi.org/10.1084/jem.20061890
17. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; https://doi.org/10.1158/0008-5472.CAN-10-2788
18. Greyer M, Whitney PG, Stock AT, Davey GM, Tebartz C, Bachem A, Mintern JD, Strugnell RA, Turner SJ, Gebhardt T, et al. T cell help amplifies innate signals in CD8(+) DCs for optimal CD8(+) T cell priming. Cell Rep 2016; 14:586-97; PMID:26774484; https://doi.org/10.1016/j.celrep.2015.12.058
19. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; https://doi.org/10.1038/nri3845
20. + T cells in the memory population mediate potent protective immunity. Immunity 2013; 38:1250-60; PMID:23746652; https://doi.org/10.1016/j.immuni.2013.05.009
21. Chu HH, Chan S-W, Gosling JP, Blanchard N, Tsitsiklis A, Lythe G, Shastri N, Molina-París C, Robey EA. Continuous effector CD8(+) T cell production in a controlled persistent infection is sustained by a proliferative intermediate population. Immunity 2016; 45:159-71; PMID:27421704; https://doi.org/10.1016/j.immuni.2016.06.013
22. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID:19423728; https://doi.org/10.1182/blood-2008-12-195792
23. Odorizzi PM, Pauken KE, Paley Ma, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015; 212:1125-37; PMID:26034050; https://doi.org/10.1084/jem.20142237
24. Tessmer MS, Fugere C, Stevenaert F, Naidenko OV, Chong HJ, Leclercq G, Brossay L. KLRG1 binds cadherins and preferentially associates with SHIP-1. Int Immunol 2007; 19:391-400; PMID:17307799; https://doi.org/10.1093/intimm/dxm004
25. Henson S, Franzese O, Macaulay R, Libri V, Azevedo R, Kiani-Alikhan S, Plunkett F, Masters J, Jackson S, Griffiths S, et al. KLRG-1 signalling induced proliferative dysfunction and defective Aktser473 phosphorylation in highly differentiated human CD8+ T cells. Blood 2009; 113:1-3; PMID:19406987; https://doi.org/10.1182/blood-2009-01-199588
26. Kanakry CG, Ganguly S, Luznik L. Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent. Oncoimmunology 2015; 4:e974393; PMID:25949893; https://doi.org/10.4161/2162402X.2014.974393
27. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Proietti E, Belardelli F. Cyclophosphamide induces type I interferon and augments the number of CD44 hi T lymphocytes in mice:implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870; http://www.bloodjournal.org/content/95/6/2024
28. Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest 2016; 126:2404-11; PMID:27367184; https://doi.org/10.1172/JCI86892
29. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69:3077-85; PMID:19293190; https://doi.org/10.1158/0008-5472.CAN-08-2281
30. Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; https://doi.org/10.1084/jem.20101159
31. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, et al. IFN-a enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 2009; 182:7398-407; PMID:19494262; https://doi.org/10.4049/jimmunol.0802982
32. Hanoteau A, Moser M. Chemotherapy and immunotherapy:a close interplay to fight cancer? Oncoimmunology 2016; 5:e1190061; PMID:27622046; https://doi.org/10.1080/2162402X.2016.1190061
33. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016; 22:433-8; PMID:26901407; https://doi.org/10.1038/nm.4051
34. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; https://doi.org/10.1126/science.aaa1348
35. Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen D, Kurachi M, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 2016; 2807:1-10; PMID:27789795; https://doi.org/10.1126/science.aaf2807